Minimum Lot Size
Issue Open Date
Issue Close Date
Hyderabad-based-Indian drug-maker was established in 1978 as a contract manufacturer of small volume liquid parenteral products, to become one of the largest and fastest growing injectable-focused companies, with a global footprint across 60 countries, including the United States, Europe, Canada, Australia, India and other markets. The company operates a Business to Business (B2B) model and claims an excellent track record in the development, manufacturing and marketing of complex injectables. The company has extensive portfolio of complex products supported by internal R&D and regulatory capabilities. The manufacturing facilities of the company have been approved by the US Food and Drug Administration (USFDA) and United Kingdom Medicines and Healthcare Products Regulatory Agency (UK MHRA).
|S.No.||1 - Company||2 - Directors||3 - Promoters|
|Entity Name||By the Company||Against the Company||By the Director||Against the Director||By the Promoter||Against the Promoter|
|Material civil cases||-||-||-||-||40||-|
|Amt. (In Million Rs.)||-||92.45||-||-||40||-|
|Gross Operating Income||27724.08||21297.67||16716.82|
|Cost of Employee & Inventory||14581.85||11540.04||9031.38|
|Profit Before Tax||9928.66||6862.78||5014.65|
|Profit After Tax||7728.58||4518.56||3210.51|
The promoters of the company are Shanghai Fosun Pharmaceutical (Group) Co. Ltd and Fosun Pharma Industrial Pte. Ltd.
Gland pharma is a pure play in injectable business with a portfolio of complex products supported by internal Research and Development department. Therefore, the company has no competitors in the Indian economy. On the global front, the company has two competitors Recipharm and Lonza having their headquarters in Sweden and Basel, Switzerland.
The object of the Offer for Sale is to allow the shareholders to sell an aggregate of up to 34,863,635 Equity Shares held by them. The company will not receive any proceeds from the Offer for Sale. Offer for Sale Size is of 34,863,635 Equity Shares of FV ₹1 aggregating up to ₹5,229.55 Cr.
The company has planned to raise fresh capital comprising an aggregate of 8,333,333 shares having FV of ₹1 aggregating up to Rs. 1,250 Cr at the upper price band of Rs. 306. The net proceeds will be utilized majorly for taking care of working capital requirements and funding capital expenditures while rest will be utilized for other corporate purposes.